drugset / Trial / NCT03182413

Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation

NCT03182413

RandomizedCrossoverQuadruple-blindTreatment

Summary

Study Objectives: THN102 is a new combination between modafinil and flecainide low-dose, a documented glial connexin inhibitor. Efficacy of THN102 was compared to modafinil and to placebo on parameters impaired by total sleep deprivation (SD, lasting 40h). Methods: 20 healthy male subjects participated in a double-blind, randomised, incomplete-block 3-period cross-over trial involving 5 treatments (n=12 per group): placebo (PBO), modafinil 100 mg (MOD), and combinations THN102 (modafinil 100 mg and 1, 3 or 9 mg flecainide as THN1, THN3 and THN9), as 3 oral doses over 18h.

Timeline

Start
2015-09
Primary completion
2015-12
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Modafinil Small molecule 100 mg Oral
Subject flecainide Small molecule 1 mg Oral
Subject flecainide Small molecule 3 mg Oral
Subject flecainide Small molecule 9 mg Oral

Indications

No indication recorded.